Sativa Wellness says research paper suggests cannabinoids may treat some lung diseases

Sativa Wellness Group Inc (LON:SWEL) said new research suggests cannabinoids may help treat inflammatory lung disease. The paper follows collaboration with King’s College London and includes the results of an investigation on the potential therapeutic use of cannabinoids for the treatment of respiratory diseases. The company said the primary purpose of the study was to investigate the anti-inflammatory effects of two of the non-psychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG) alone and in combination, in a model of pulmonary inflammation. READ: Sativa Wellness says trading goes strongly after first-quarter revenues, profits soar Sativa said the results suggest a combination of CBD and CBG have “significant anti-inflammatory activity” in the lung. The work builds on previous research suggesting cannabinoids are promising treatments for inflammatory diseases. The company added the research has also identified that the formulation for administering cannabinoids is critically important to obtain efficacy and “highlights the importance of choosing an appropriate formulation to obtain optimal benefit from administering cannabinoids”. "We have actively supported research now for over 2 years to identify the therapeutic benefits cannabinoids can have on medical conditions. Research is something we as a company believe is essential to inform the public and we are delighted to have seen such positive results identified. Sativa Group will continue to invest in scientific research to ensure that the cannabinoid products it develops under 'Goodbody Botanicals' and 'Goodbody Store', deliver the appropriate benefits", Sativa’s executive chairman Geremy Thomas said in a statement.